ViaCyte, Inc.

141 articles about ViaCyte, Inc.

• ViaCyte to Present at the Raymond James 2021 Human Health Innovation Conference

  6/16/2021

    ViaCyte, Inc. announced today that Michael Yang , President & CEO, and Brittany Bradrick , CFO & COO, will present at the Raymond James 2021 Human Health Innovation Conference on Wednesday, June 23, 2021.

• ViaCyte Announces Closing of $45 Million Financing to Advance Broadest Portfolio of Stem Cell-Derived Therapies for Type 1 Diabetes

  6/9/2021

  ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the closing of a $45 million financing tranche that brings the total Series D financing to more than $115 million.

• ViaCyte Appoints Dr. Evert Kroon as Interim Chief Scientific Officer

  6/8/2021

  ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with diabetes, announced the appointment of ViaCyte's current Vice President of Translation Research Evert Kroon, PhD, to serve as interim Chief Scientific Officer following the departure of CSO Kevin D'Amour, PhD.

• ViaCyte to Present Late-Breaking Data at the American Diabetes Association's 81st Scientific Sessions

  6/1/2021

  ViaCyte, Inc. announced today presentation of a late-breaking ePoster at the upcoming American Diabetes Association's Virtual 81st Scientific Sessions to be held on June 25-29, 2021.

• ViaCyte to Present at the Jefferies Virtual Healthcare Conference - May 26, 2021

  5/26/2021

  ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with diabetes, announced that Michael Yang, President & CEO, will present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 1:00 p.m. ET.

• ViaCyte and Gore Expand Collaboration to Develop Novel Membrane and Device Technologies that Enhance Delivery of Cell Replacement Therapies for Diabetes

  3/2/2021

  Agreement extends research and clinical development across ViaCyte's full product portfolio and Gore's full materials and device proprietary technologies

• ViaCyte Announces Initiation of Phase 2 Study of Encapsulated Cell Therapy for Type 1 Diabetes Patients

  2/3/2021

  ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced that the first type 1 diabetes (T1D) patients have been implanted in a Phase 2 clinical study utilizing encapsulated delivery of cells.

• 

  BioSpace Movers & Shakers, Jan. 29

  1/29/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• ViaCyte Appoints Michael Yang President and CEO and Provides Company Update

  1/27/2021

  ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the appointment of Michael Yang to President and CEO and as a member of ViaCyte's Board of Directors.

• ViaCyte Appoints Dr. Manasi Sinha Jaiman as Vice President, Clinical Development

  8/13/2020

  ViaCyte, Inc. , a clinical stage regenerative medicine company, today announced the appointment of Manasi Sinha Jaiman , M.D., M.P.H. as Vice President, Clinical Development. Dr. Jaiman joins ViaCyte from Covance Clinical Development Services, where she was Senior Medical Director. She was also an attending physician at Harvard Medica

• ViaCyte and Gore Enter Clinical Phase Agreement Based on Novel Membrane Technology for PEC-Encap Product Candidate

  8/5/2020

  Clinical evaluation of PEC-Encap has resumed using sentinels created with the novel membrane; preclinical and initial clinical data suggest the novel membrane can mitigate the foreign body host response   [05-August-2020]   SAN DIEGO and NEWARK, Del. , August 5, 2020 /PRNewswire/ --  ViaCyte, Inc. , a clinical stage regenerative medicine company, and W. L. Gore & As

• 

  BioSpace Movers & Shakers, July 17

  7/17/2020

  Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.

• ViaCyte Appoints Brittany Bradrick as Chief Financial Officer

  7/13/2020

  ViaCyte, Inc. , a clinical stage regenerative medicine company, today announced the appointment of Brittany Bradrick as Chief Financial Officer. Ms. Bradrick joins ViaCyte from Insulet Corporation where she was Vice President, Strategy and Corporate Development. Prior to that, she was Director, Business Development and Alliance Manageme

• ViaCyte to Present at the Jefferies Virtual Healthcare Conference

  5/28/2020

  ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind , Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9. The company recently announced a $27 million financing  to advance

• ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes

  5/26/2020

  PEC-Direct: Clinical data from ViaCyte's product candidate has shown that implanted cells, when effectively engrafted, are capable of producing circulating C-peptide, a biomarker for insulin, in patients with type 1 diabetes PEC-Encap: ViaCyte's cell therapy product candidate designed to treat all patients with insulin requiring diabetes is being studied in the clinic utilizing an encapsulated delivery technology developed in collaboration with W.L. Gore & Associates

• ViaCyte to Present at Biotech Showcase 2020 in San Francisco

  1/8/2020

  ViaCyte, Inc., a privately-held regenerative medicine company, announced that ViaCyte's President and CEO Paul Laikind, Ph.D. will present at Biotech Showcase™ 2020, to be held January 13 to 15 at the Hilton San Francisco Union Square..

• ViaCyte to Present at ISSCR International Symposium: Stem Cell Biology to New Therapies

  11/4/2019

  For type 1 diabetes, ViaCyte has two product candidates, PEC-Direct and PEC-Encap, in clinical trials.

• ViaCyte to Present Preliminary PEC-Direct Clinical Data at Cell & Gene Meeting on the Mesa

  10/3/2019

  First demonstration of insulin production in patients from a stem cell-derived islet replacement therapy

• ViaCyte to Expand Board of Directors with Two New Appointments

  7/24/2019

  ViaCyte, Inc., a privately-held regenerative medicine company, today announced the appointment of Paul J. Hastings and Ian F. Smith to the Company's Board of Directors.

• ViaCyte Appoints Sandra E. Poole to Board of Directors

  6/27/2019

  Ms. Poole brings more than 25 years of biopharmaceutical experience in product development, from research through commercialization, to ViaCyte's team.